The pharmacology of brentuximab bedouin

Abstract

Hodgkin's lymphoma is a tumor originating in white blood cells. Treatment with modern chemo- and radiotherapy has an excellent prognosis. Despite this fact, 15-20% of patients go into relapse. Brentuximb Vedotin is a monoclonal antibody against CD30. It is now being used in the treatment of refractory/relapsed Hodgkin's lymphoma.